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Abstract: – Employing tryptamine or tryptophane methylester hydrochloride and (Sp)-2-
formylferrocene-1-carboxylate as precursors by means of Pictet-Spengler reactions and 
subsequent intramolecular acylation effected by cyanuricfluoride or carbonyldiimidazole (CDI), 
the first representatives of ferrocene-containing -carboline derivatives including polycyclic 
ferroceno/fused lactames, were prepared. In the course of CDI-mediated tandem cyclization of a 
tryptophane-derived carboxyferrocenyl-substituted -carboline, a ring enlargement simultaneously 
taking place with the loss of the 5-C5H5Fe
+
 fragment of the fused ferrocene moiety, effected by 
the coordinating imidazole released from the reagent, led to a 4H-cyclopenta[7,8]azonino[5,4-
b]indole as a minor product. The constitution and relative configuration of the new compounds 
with the elements of planar-, central- and conformational chirality were established by NMR 
methods including HMQC, HMBC and NOESY measurements supported by DFT modeling 
studies. 
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1. Introduction  
 
There is a continuous interest in the -carboline alkaloids representing an important class of 
synthetic and naturally occurring heterocycles with a wide spectrum of valuable pharmacological 
properties [1–6]. In the recent decades it was also demonstrated that -carboline alkaloids may have a 
pronounced potential as anti-cancer agents [7–16], which can act through different mechanisms 
including eg. DNA-intercalation [17], inhibition of Topoisomerase I and II [18] and CDK (cyclin-
dependent kinases) [19, 20]. On the other hand, it is well documented that the replacement of an 
aromatic nucleus in certain organic compounds for a ferrocene unit can lead to such products which 
possess enhanced biological activity relative to that displayed by the parent molecule [21], and a 
variety of functionalized ferrocenes with relatively simple structures has been shown to exhibit 
valuable biological effects [2232]. In this regard our group has also synthesized and characterized a 
wide variety of ferrocene-containing heterocycles of potential biological importance [3346] and – in 
four cases [4750]  with proved in vitro anticancer activity against human malignant cell lines. Since 
to our best knowledge metallocene-based -carbolines are not known in the literature, in the frame of 
our ongoing research we targeted the preparation and structural analysis of ferrocene-containing 
heterocycles with 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole residue including diastereomeric 
6,7,12,12b-tetrahydro-4H-ferroceno[1,2]indolizino[8,7-b]indol-4-ones, the first representatives of 
novel classes of alkaloid-like fused metallocenes with the elements of planar-, central- and 
conformational chirality which will be subjected to in vitro anti-cancer assays on selected human 
malignant cell lines. 
 





2. Results and Discussion 
 
2.1. Optimization of Pictet-Spengler conditions 
 
At the beginning of the synthetic pathway we searched for optimal conditions for the crucial 
Pictet-Spengler cyclizations of imines 2a,b and 6a,b resulted from facile condensations of tryptamine-
based amine components with formylferrocene (1) and (Sp)-2-formylferrocene-1-carboxylic acid (5) 
[46], respectively, (cf. Methods A and B, Scheme 1). The cyclization of 2a, selected as model 
precursor with the simplest structure in hand, was first attempted by four methods (CG) employing 
different acidic conditions to construct 1-ferrocenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 3a. 
Since the prolonged treatment (24 h) of 2a with acetic acid at reflux temperature proved to be the most 
efficient protocol (Method G) to promote the formation of 3a (isolated yield 80%), the same 
conditions were applied for the cyclization of iminoester 2b affording an approximately 5:1 mixture of 
diastereomers 3b and 4b. The cyclizations of tryptophane-based imines 6a,b, were also performed 
under the conditions of Method G resulting in zwitterionic -carboline carboxylates as mixtures of 
diastereomeric pairs 7a/8a and 7b/8b, respectively. Although 8a could be separated as a minor 







With the intention of constructing novel ferroceno-fused ring systems with alkaloid-like 
structures of potential biological interest first we attempted the cyclization of 7a by two versions of 
carboxyl-activation effected by cyanuricfluoride and carbonyldiimidazole (CDI) in the presence of 
catalytic amount of triethylamine hydrochloride representing Methods H and I, respectively (Scheme 
2). The reactions gave the fused lactame 9a, with “S”-configuration at the C12b stereogenic center and 
“M” helical chirality associated with the conformation adopted by the tetrahydropyridine ring (referred 
as ring C in the subsequent discussion), in mediocre yields (45% and 60%). The analogous cyclization 




of 8a was carried out by Method I resulting in diastereomeric lactame 12a with “R”-configuration at 
the C12b stereogenic center and “P” helical chirality of ring C in acceptable yield (44%). (The 
structure determination of the fused lactames will be discussed in detail in the next session.) We also 
checked the accessibility of 9a and 12a by a reverse sequence involving primary acylation followed by 
acid-catalyzed tandem cyclization. However, amide 11 obtained by a facile reaction of tryptamine with 
(Sp)-2-formyl-1-fluorocarbonylferrocene (10) [46] in THF (Method J) resisted to any further 
conversions under each condition proved to be efficient in promoting Pictet-Spengler cyclization of 
imine-type substrates (Scheme 2).  
 
Scheme 2 
Finally, a third version of sequential cyclization procedure employing Method I based on 
primary carboxyl-activation was attempted to convert imine 6a into fused lactames (9a and 12a) in a 




single operation. To our surprise, the reaction resulted in diastereomer 12a as the major product 
(58%), while 9a was formed as the minor component isolated in low yield (24%). This one-pot 
protocol also proved to be successful in promoting a tandem cyclization of tryptophane-based imine 
6b to construct diastereomeric esters 12b (53%), 9b (5%) and 9b/inv (15%). Pointing to the relative 
stability of the separable conformers, on heating in DMSO-d6 solution in an NMR tube at 90 
o
C under 
an argon atmosphere for ca. 30 min (Method K), 9b/inv with “P” helical chirality of ring C was 
completely transformed into 9b with “M” helical chirality of ring C. 
Besides the ferroceno-fused -lactams a fulvene-fused azoninone (13b) with E-lactame unit 
could also be isolated in low yield (6%) from the reaction mixture. The formation of this purely 
organic product takes place by trans-annular opening of the fused -lactame fragment along the C12b-
N5 bond associated with decomposition of the ferrocene residue, probably induced by imidazole of 
CDI-origin. This view gains support from the imidazole-mediated transformations of 9b and 9b/inv 
carried out in DMF at 110 
o
C affording 13b in low yields (22% and 16%, respectively). The modified 
conditions employing elevated temperatures or prolonged reaction times did not led to higher yields of 
13b, but resulted in the formation of substantial amounts of tarry substances. This transformation can 
be interpreted by the coordination of imidazole to the 5-C6H5Fe
+
 residue to give intermediate I which 
undergoes fragmentation affording 13b and 1,3-diazaferrocene II. Probably due to its uncontrolled 
decomposition processes II could not be isolated from the reaction mixture.  
The cyclization reactions of esters 7b and 8b were also accomplished under the conditions of 
Method I employing CDI as coupling reagent. Accordingly, the reaction of 7b afforded a mixture of 
9b (37%), azoninone 13b (9%) and -lactame 14b (22%) as a result of the acylation of N2- and N9 
atoms, respectively (Scheme 3). The decreased propensity of N2 to undergo intramolecular acylation 
is probably due to the proximity of the bulky methoxycarbonyl group, thus increasing the chance of 
indole N9 atom to be involved in the cyclization step accompanied by spontaneous dehydrogenation of 
the tetrahydropyridine ring finally affording 14b. Under the same conditions -carboline 8b got 
converted again into -lactame 14b and -lactame 12b in comparable yields (30% and 26%, 
respectively). Since in 12b the 5-C6H5Fe
+
 fragment is situated in the endo position of decreased 
accessibility, this -lactame seems to resist the imidazole-mediated trans-annular ring opening finally 
leading to 13b. It must be pointed out here that – contrary to 9b and 9b/inv – 9a did not undergo an 
analogous transformation with the cleavage of the C12b-N5 bond, which is probably facilitated by the 
electron withdrawing effect of the adjacent methoxycarbonyl group. 
 
Scheme 3. 
From the aspect of the stereochemical outcome of the tandem cyclizations of imines 6a,b, it 
must be pointed out that under the conditions promoting the primary activation of the carboxyl group, 
the formation of the isomers with “R”-configuration at the C12b stereogenic center is preferred over 
that of the diastereomers with “S”-configuration at the same stereogenic center irrespective of the 
helical chirality of ring C (isolable yields: 58%/24% for 12a/9a and 53%/(15%+5%) for 
12b/(9b/inv+9b), respectively). On the basis of the results of the experiment conducted under forced 
conditions (cf. Method K: Scheme 2) and supported by the modeling studies discussed below, it seems 




that it is 9b/inv which is formed as the primary product in the tandem cyclization reaction of 6b. In 
order to disclose the pathways of CDI-promoted tandem cyclization reactions accounting for this 
diastereoselectivity, we undertook comparative DFT modeling studies [51] carried out at B3LYP level 
of theory [52] with 6-31 G(d,p) basis set [53] on the cyclic N-acyliminium intermediates 15a and 15b 
supposed to be resulted from the cyclization of 6a,b, and stabilized by the highly electron-donor 






























Scheme 4 DFT representation of the interconversions of possible diastereomeric intermediates and 
lactame products involved in the CDI-mediated tandem cyclizations. The relative total electronic 
energy values and activation barriers [kJ/mol] were calculated at B3LYP/6-31 G(d,p) level of theory 
using IEFPCM to imitate the experimental conditions (DMF=36.7). 




The geometry optimization found conformers 15a,b/1 and 15a,b/2 (Scheme 4) as local 
minima on the potential energy surfaces (PES) preformed for the crucial bond formation between the 
C12a and C12b atoms to yield intermediates 16a,b/c and 16a,b/t of which deprotonation finally leads 
to two types of diastereomeric products 9a,b and 12a,b, respectively. Using QST2 method [54] the 
transition states of the crucial cyclization steps 15/1→16/c and 15/2→16/t were identified on the PES 
as saddle points and confirmed by IRC analysis [55]. The total electron energy values for all optimized 
structures were recalculated with IEFPCM solvent model [56] employing the dielectric constant of 
DMF (=36.7) to provide a more realistic representation of the experimental conditions. Finally, 
considering the E and E# values presented on Scheme 4 it can be stated that the results of modeling 
studies provide a satisfactory support for the proposed reaction pathways outlined above, as both the 
relative energetics of the relevant conformers of the primarily formed N-acyliminium intermediates 
(15a,b/1 and 15a,b/2) and the activation barriers of their ring closures, ultimately determining the 
relative configuration of the products, are in good agreement with the diastereoselectivity experienced 
in the CDI-mediated tandem cyclization reactions of imines 6a,b. On the other hand, the higher 
activation barriers of the ring closures of 15a,b/1 (+38.2 kJ/mol and +42.5 kJ/mol) relative to those of 
15a,b/2 (+31.4 kJ/mol and +29.2 kJ/mol) seem to correlate with the opposite signs of the energetics 
calculated for these elementary steps [E(16a/c15a/1)/(16b/c15b/1)=+6.8 kJ/mol/+6.0 kJ/mol, vs. 
E(16a/t15a/2)/(16b/t15b/2)= 8.6 kJ/mol/16.8 kJ/mol]. The total electron energy values of the 
possible conformer pairs of the lactame products and the activation barriers of their interconversions 
were also calculated by the aforementioned DFT method and solvent model (Scheme 4). Although the 
results indicate that - except for 9b/inv→9b - the ring inversions of the isolated lactames 9a and 12a,b 
are not favored processes in terms of relative energetics, due to their low activation barriers the 
presence of minimal amounts of conformers 9a/inv and 12a,b/inv (<1%) cannot be ruled out in the 
appropriate reaction mixtures or in the dissolved samples subjected to NMR measurements. However, 
since the transition state was located with a fixed position of the methoxycarbonyl group, the 
calculated activation barrier for ring inversion 9b/inv→9b (+11.6 kJ/mol) is certainly lower than the 
real one of which height must substantially be increased by the rotation of the bulky substituent which, 















Figure 1 Selected bonding orbitals of conformers 15a,b/2, the precursors of ring closures finally 
leading to lactames 12a,b, determined by B3LYP/6-31 G(d,p) analysis performed on optimized 
structures. 
HOMO of 15a/2 
E= 8.51 eV 
HOMO-5 of 15a/2 
E= 10.39 eV 
HOMO-2 of 15a/2 
E= 9.57 eV 
HOMO of 15b/2 
E= 8.39 eV 
HOMO-2 of 15b/2 
E= 9.40 eV 
HOMO-5 of 15b/2 
E= 10.30 eV 




The relative energetics of the conformer pairs 15a/115a/2 and 15b/115b/2, respectively, 
preformed for the crucial cyclization steps responsible for the stereochemical outcome of the overal 
reactions, are also worth for discussion based on the analysis of relevant bonding orbitals (Figure 1). 
Accordingly, it might be concluded that the extra stabilization of conformers type 15/2 relative to that 
of alternative conformers type 15/1 can at least partially be attributed to the delocalization of HOMO-5 
presenting a weak bonding between the iron center and the proximal indole ring. Iminium ions 15a,b/2 
are also stabilized by interactions of the cationic center with the donor indole and ferrocene moieties, 
as demonstrated by HOMO and HOMO-2, respectively. 
2.3. Structure determination of the novel compounds 
 
The spectroscopic data listed in the Experimental part are consistent with the structures of 
novel compounds 2a,b, 3a,b 4b, 6a,b, 7a,b, 8a,b, 9a,b, 9b/inv, 11, 12a,b, 13b and 14b, however the 
following points are necessary to be highlighted.  
Due to the presence of incorporated ferrocene- and/or tryptophane fragments with fixed 
elements of chirality, the absolute configurations of 3b, 4b, 6b, 7a,b, 8a,b, 9a,b, 9b/inv, 12a,b and 
13b follow from their relative configurations. 




J couplings between the signals of 




C-HMBC method for 3a,b 4b, 
7a,b and 8a,b indicate the presence of the -carboline skeleton, i.e. the condensation of the 
tetrahydropyridine ring to the indole residue. In a similar way, the polycyclic constitution of 9a,b, 
9b/inv and 12a,b is unequivocally proved by the cross peak correlations between the signals 





HMBC spectra. In accord with their relative configuration, the NOESY spectra of 9a, 9b and 9b/inv 
disclosed that H12b is situated in the proximity of the protons of the freely rotating 5-C5H5 residue. In 
9b and 9b/inv the “S” configuration of the C6 stereogenic center was evidenced by NOE’s detected 
between protons H12b and H6A being in relative 1,3-cis position on the ring system. On the other 
hand, in 12a and 12b the “R” configuration of the C12b stereogenic center associated with the endo 
orientation of the 5-C5H5 ring is evidenced by the NOE’s generated by its interactions with H7A and 
the indole NH proton, respectively. In keeping with the results of NOESY experiments, in the 
optimized structures of these compounds H7A, attached to ring C with half chair conformation of “P”-
helicity, is situated in endo-axial position in the proximity of the 5-C5H5 ring. Being in the shielding 
region of the indole ring, 
1
H resonances of this residue measured for 12a and 12b (3.68 and 3.70 ppm, 
resp.) are significantly upfield-shifted relative to those measured for diastereomers 9a,b and 9b/inv 
carrying the 5-C5H5 ring in exo site of the polycyclic skeleton (4.064.31 ppm). The NOESY 
experiments carried out for 9a,b and 9b/inv detected an additional interaction between H12b and H6A 
atoms. Supporting the results of DFT modeling studies on 9a,b, the coupling patterns of H6- and H7 
multiplets discernible in their 
1
H-NMR spectra refer to “M” helical chirality of ring C with a half chair 
conformation carrying H6A and H7B in relative 1,2-diaxial position [J(H6A/H7B)=11.6 Hz and 11.8 Hz 
for 9a and 9b, resp.]. On the other hand, the opposite helical chirality (“P”) of ring C in 9b/inv and 
12b, carrying the methoxycarbonyl group in axial position, is reflected from the simple broadened 
doublet split of the signal of the H6A proton (7.1 Hz and 7.5 Hz, resp.) due to an interaction with the 
H7A proton and a negligible coupling with the H7B proton. In 12a the same conformation of ring C 
associated with helical chirality “P” is also evidenced by the coupling pattern of the signals originated 
from the skeletal protons, which indicates only a weak interaction characterized by 2.0 Hz between 
H6A and H7B. In the 
1
H-NMR spectrum of 12a the assignments of H6A- and H6B signals were 
supported by a NOESY experiment disclosing a significant interaction between protons H6B and 
H12b. Accordingly, the signal of H6B is significantly upfield-shifted relative to that of the equatorial 
H6A positioned in the proximity of the lactame carbonyl group exerting a significant anisotropic 
deshielding effect on the latter resonance (3.54 ppm and 4.98 ppm, resp.). It must be pointed out that 
in the 
1
H-NMR spectrum of 9a the resonance due to equatorial proton H6B, (5.18 ppm) situated nearly 
in the plane of the lactame carbonyl group, is significantly downfield shifted relatively to that 
measured for H6A (3.79 ppm) in axial position.  




In order to detect the particular conformers of the fused -lactames we attempted to register 
their 
1
H-NMR spectra at low temperature using CD2Cl2 as solvent, however these efforts failed due to 
severe solubility problems. Instead, the almost exclusive presence of the preferred conformers of 9a, 
and 12a,b was supported by comparative NMR-GIAO calculations [57] carried out for the optimized 
structures of the corresponding conformer pairs (Table 1) by B3LYP functional using the extended 6-
311 ++G(2d,p) basis set [58]. Although no exact data can be given for the ratio of the particular 
components involved in the possible equilibrium ring inversion processes, in each studied case the 
difference between the calculated- and experimental chemical shifts and separation of the skeletal H6 
signals (cf. 9a-9a/inv and 12a-12a/inv) unambiguously refer to a strong dominance of the 
diastereomer supposed to be detected by NMR experiments over its counterparts with reversed helicity 
of ring C. Supporting this view, the highly diagnostic vicinal coupling constants J(H6A/H7B) and 
J(H6A/H7A) are in good accord with the values calculated by a particular version of Karplus-equation 
using a parameter set composed for a general N-CH2-CH2-C sequence [59] and the dihedral angles 
found in the modeled structures of the isolated -lactames (Table 1). It is also important to note here 
that the substantial dismatch between the calculated and measured values of J(H6A/H7B) rules out the 
presence of diastereomers 9a/inv, 12a/inv and 12b/inv in significant amounts in the solutions 
subjected to NMR studies. Finally, the alternative conformations of ring C with opposite helicity in 
diastereomers 9b and 9b/inv are conclusively evidenced by the highly similar calculated- and 
experimental NMR parameter pairs listed in Table 1. This stereochemical relation was also confirmed 
by ring inversion 9b/inv→9b carried out in a separate experiment under the conditions of Method K, 
as discussed above.  
The relative configurations of carboxyferrocenyl-substituted -carbolines 7a,b and 8a,b, the 
precursors of CDI-mediated cyclization reactions assumed to take place with the preservation of the 
configuration of the particular stereogenic centers, were deduced from those determined for the 
corresponding lactame products types 9 and 12. 
In compound 13b the constitution and the bent conformation of the nine-membered azonine 
ring with “E” lactame residue were established on the basis of NOESY cross-peak correlations 
between proton pairs H3/H6A, H5/H7B, H7B/H8, H12/H13 and H1/H13. 
The significant downfield shift of the H9 signal in the 
1
H-NMR spectrum of 14b (8.62 ppm) 
refers to the proximity of the oxygen atom of the carbonyl group incorporated in the -lactame ring 
fused to the ferrocene moiety. The broadened doublet signals due to H9 and H12 were unambiguously 
assigned on the basis of a NOESY interaction detected between proton pair H1/H12 being in spatial 
proximity on the rigid ring system.  
 
Table 1: 1H-NMR shifts and separation of H6A and H6B signals calculated for diastereomer pairs 9a-9a/inv, 9b-9b/inv, 12a-
12a/inv and 12b-12b/inv (rows 1-6, reference: TMS)a, dihedral angles between skeletal protons (: rows 7 and 10)b and 
vicinal coupling constants J(H6A/H7B) and J(H6A/H7A) (calculated values: rows 8 and 11, measured values: rows 9 and 12). 
 9a 9a/inv 9b 9b/inv 12a 12a/inv 12b 12b/inv 
1. H6A [ppm] (calcd.) 3.84 
c 3.47 4.18 5.28 5.00 c 3.68 5.85 c 4.84 
2. H6A [ppm] (meas.) 3.79 
c 4.26 5.49 4.98 c 5.66 c 
3. H6B [ppm] (calcd.) 4.88 
c 4.01 - - 3.24 c 4.02 - - 
4. H6B [ppm] (meas.) 5.18 
c - - 3.54 c - - 
5. H6A-H6B) [ppm] (calcd.) -1.04 
c -0.54 - - 1.96 c -0.34 - - 
6. H6A-H6B) [ppm] (meas.) -1.39 
c - - 1.76 c - - 
7. (H6A/H7B) [°] (calcd.) 162.8 79.1 167.7 73.6 74.9 157.2 77.7 150.5 
8. J(H6A/H7B) [Hz] (calcd.)
d 10.9c 1.5 11.4 1.9 1.8 c 10.1 1.6c 9.1 
9. J(H6A/H7B) [Hz] (meas.) 11.6 
c 11.8 ~0 2.0 c ~0 c 
10. (H6A/H7A) [°] (calcd.) 44.8 35.8 51.9 39.8 42.0 41.2 35.4 38.1 
11. J(H6A/H7A) [Hz] (calcd.)
d 5.9 c 7.3 4.8 6.8 6.4 c 6.5 7.4 c 7.0 
12. J(H6A/H7A) [Hz] (meas.) 5.2 
c 4.3 7.1 5.4 c 7.5 c 
a. The calculations were performed by B3LYP/NMR-GIAO method using the extended 6-311 ++G(2d,p) basis set. 
b. The values are extracted from the structures optimized by B3LYP functional employing 6-31 G(d,p) basis set. 
c. The better match between the calculated and measured values is highlighted by bold-italic fonts. 
d. Obtained by Karplus equation using values and a parameter set composed for a general N-CH2-CH2-C sequence. 
 






By means of sequential use of Pictet-Spengler and N-acylation protocols 4-oxo-6,7,12,12b-
tetrahydro-4H-ferroceno[1,2]indolizino[8,7-b]indoles, the first representatives of a novel -carboline-
based alkaloid-like ring system incorporating fused metallocene and -lactame moieties were prepared 
as single enantiomers with the elements of planar- and central chirality. The conformation and the 
relative configuration of these products were determined by combined use of one- and two-




C-NMR methods supported by theoretical NMR calculations. 
Besides the targeted -lactame products the ring closures of carboxyferrocenyl-substituted -
carbolines carrying methoxycarbonyl group in position 3 also afforded the planar chiral -lactame 
(Sp)- methyl 7-oxo-7H-ferroceno[c]indolo[3,2,1-ij][1,5]naphthyridine-2-carboxylate of which 
formation was prevented by implementing an alternative method for the construction of the desired -
lactames based on CDI-mediated tandem cyclization of simple carboxyferrocenyl-substituted 
tryptamine/tryptophane-derived imines. Possible reaction pathways accounting for the 
diastereoselectivity of the overall processes were proposed on the basis of the results obtained by 
comparative DFT modeling studies. Employing further imine precursors suitable to form a five- or 
six-membered cyclic N-acyliminium intermediate capable of acting as efficient electrophilic 
component in intramolecular Pictet-Spengler reaction, this one-pot procedure may allow the facile 
synthesis of a range of related polyheterocyclic alkaloid analogues of potential biological interest. The 
evidenced propensity of metallocene-fused lactame products to undergo trans-anullar ring opening, 
taking place with simultaneous decomposition of the organometallic fragment, can be utilized in 
design of improved protocols to provide a relatively easy access to novel classes of medium-size 




All chemicals were obtained from commercially available sources (Aldrich, Fluka) and used without 
further purification. Melting points (uncorrected) were determined with a Boethius microstage. Merck Kieselgel 
(230–400 mesh, 60 Ǻ) was used for flash column chromatography. The Rf values given for the separated 
products were determined using DCM-MeOH (20:1) as eluent on silica plate. The IR spectra were run by ATR 
(Attenuated Total Reflectance) method [60] on a Bruker IFS-55 FT-spectrometer controlled by Opus 3.0 





were recorded in DMSO-d6 or CDCl3 solution in 5 mm tubes at RT, on a Bruker DRX-500 spectrometer at 500 
(
1
H) and 125 (
13




C) The 2D-COSY, HSQC,
 
HMBC and NOESY spectra were obtained by using the standard Bruker pulse 
programs. All calculations were carried out with the Gaussian 09 suite of programs [61]. Optimized structures 
are available from the authors.  
 
4.1. Preparation of imines 2a and 6a (Method A)  
 Tryptamine (3.204 g, 20 mmol) and formylferrocene (4.281 g, 20 mmol) or (Sp)-2-formyl-ferrocene 
carboxylic acid (5.161 g, 20 mmol) were heated in MeOH (20 mL) at reflux temperature for 1 h. The reaction 
mixture was evaporated to half of its volume and diluted with water (30 mL). The precipitated solid was filtered 
off, washed with a cold mixture of MeOH-water (2:3) and dried to obtain the appropriate imine 2a or 6a. 
Analytical samples of the products were recrystallized from mixtures of DCM-hexane. 
4.1.1. (E)-N-(2-(1H-Indol-3-yl)ethyl)-1-ferrocenylmethanimine (2a) 
 Dark yellow solid. Yield: 5.840 g (82%); mp.: 67-70 °C; IR (cm−1): ~3300-2900, 1643, 1446, 1245, 
1105, 1043, 1021, 810, 737. 
1
H NMR (CDCl3): 8.30 (s, 1H, NH); 8.03 (s, 1H, CH=N); 7.72 (d, J=7.4 Hz, 1H, 
H4); 7.36 (d, J=7.4 Hz, 1H, H7); 7.21 (t, J=7.4 Hz, 1H, H5); 7.17 (t, J=7.4 Hz, 1H, H6); 7.05 (br s, 1H, H2); 
4.64 (t, J=1.8 Hz, 2H, H2’,5’); 4.37 (t, J=1.8 Hz, 2H, H3’,4’); 4.06 (s, 5H, 5-C5H5); 3.84 (t, J=6.8 Hz, 2H, N-
CH2); 3.17 (t, J=6.8 Hz, 2H, C-CH2); 
13
C NMR (CDCl3): 162.0 (CH=N); 136.8 (C7a); 128.0 (C3a); 122.6 (C2); 
122.3 (C6); 119.6 (C5); 119.4 (C4); 114.4 (C3); 111.7 (C7); 80.5 (C1’); 71.0 (C3’,4’); 69.5 (5-C5H5); 69.0 
(C2’,5’); 62.3 (N-CH2); 27.3 (C-CH2); Anal. Calcd. for C21H20FeN2 (356.25): C, 70.80; H, 5.66; N, 7.86. Found: 
C: 70.70; H: 5.74; N, 7.91%.  
 




4.1.2. (Sp,E)-2-(((2-(1H-Indol-3-yl)ethyl)imino)methyl)ferrocene carboxylic acid (6a) 
Dark red solid. Yield: 6.084 g (76%); mp.: 85-87 °C; []D
25
: +42.2° (EtOH c = 0.084 g/100 mL); IR 
(cm
−1
): ~3600-2700, 1710, 1645, 1585, 1437, 1340, 1230, 1106, 1003, 821, 741. 
1
H NMR (DMSO-d6): 10.91 (s, 
1H, NH); 8.49 (s, 1H, CH=N); 7.63 (d, J=7.3 Hz, 1H, H4); 7.33 (d, J=7.3 Hz, 1H, H7); 7.07 (t, J=7.3 Hz, 1H, 
H6); 7.01 (t, J=7.3 Hz, 1H, H5); 7.23 (br s, 1H, H2); 5.11 (br s, 1H, H5’); 4.82 (br s, 1H, H3’); 4.70 (t, J=1.8 Hz, 
1H, H3’); 4.05 (s, 5H, 5-C5H5); 3.90 (t, J=6.4 Hz, 2H, N-CH2); 3.10 (t, J=6.4 Hz, 2H, C-CH2); due to exchange 
processes the signal of CO2H proton could not be detected in the spectrum; 
13
C NMR (DMSO-d6): 171.5 (CO2H) 
167.5 (CH=N); 137.2 (C7a); 127.9 (C3a); 124.0 (C2); 121.9 (C6); 119.3 (two coalesced lines, C4 and C5); 112.3 
(C7); 112.0 (C3); 76.4 (C5’); 75.9 (C1’); 75.5 (C4’); 73.6 (C3’); 71.9 (5-C5H5); 70.2 (C2’); 57.8 (N-CH2); 26.5 
(C-CH2); Anal. Calcd. for C22H20FeN2O2 (400.26): C, 66.02; H, 5.04; N, 7.00;. Found: C: 65.94; H: 5.12; N, 
7.08%. 
4.2. Preparation of imines 2b and 6b (Method B)  
 A mixture of (L)-tryptophane methylester hydrochloride (5.094 g, 20 mmol), Na2CO3, (2.650 g, 25 
mmol), water (40 mL) and DCM (80 mL) was intensively stirred for ca. 5 min., the phases were separated. The 
aqueous solution was extracted with DCM (3x30 mL). To the combined organic phase formylferrocene (4.281 g, 
20 mmol) or (Sp)-2-formyl-ferrocene carboxylic acid (5.161 g, 20 mmol) was added. The solution was dried on 
Na2SO4 then evaporated to dryness to obtain a solid residue which was trituated with cold MeOH, filtered off 
washed thoroughly with water and dried. Analytical samples of the products were recrystallized from mixtures 
of DCM-hexane.   
4.2.1. Methyl (S,E)-2-(ferrocenylmethyleneamino)-3-(1H-indol-3-yl)propanoate (2b)  
Dark yellow solid. Yield: 7.883 g (93%); mp.: 78-81 °C; []D
25: −57.5° (EtOH c = 0.053 g/100 mL); IR 
(cm
−1
): ~3600-2700, 1742, 1600, 1580, 1437, 1340, 1244, 1100, 1012, 833, 746. 
1
H NMR (DMSO-d6): 10.82 (s, 
1H, NH, indole); 8.36 (s, 1H, CH=N); 7.61 (d, J=7.6 Hz, 1H, H4); 7.30 (d, J=7.6 Hz, 1H, H7); 7.08 (t, J=7.6 Hz, 
1H, H6); 6.96 (t, J=7.6 Hz, 1H, H5); 7.09 (br s, 1H, H2); 4.74 (t, J=18.0 Hz, 2H, H2’,5’); 4.40 (t, J=1.8 Hz, 2H, 
H3’,4’); 4.51 (dd, J=9.4 and 4.4 Hz, H, N-CH); 4.10 (s, 5H, 5-C5H5); 3.76 (s, 3H, CO2CH3), 3.45 (dd, J=14.7 
and 4.4 Hz, 1H, C-CHAHB); 3.22 (dd, J=14.7 and 9.7 Hz, 1H, C-CHAHB); 
13
C NMR (DMSO-d6): 171.8 
(CO2CH3); 161.2 (CH=N); 136.4 (C7a); 127.4 (C3a); 124.1 (C2); 121.5 (C6); 119.0 (C5);118.6 (C4), 112.5 
(C7); 110.0 (C3); 80.1 (C1’); 71.0 (C3’,4’); 69.2 (5-C5H5); 68.3 (C2’,5’); 71.2 (N-CH); 53.6 (CO2CH3); 29.1 
(C-CH2); Anal. Calcd. for C23H22FeN2O2 (414.29): C, 66.68; H, 5.35; N, 6.76;. Found: C: 66.85; H: 5.41; N, 
6.65%. 
4.2.2. (Sp,S,E)-2-(((1-Methoxycarbonyl-2-(1H-indol-3-yl)ethyl)imino)methyl)ferrocene carboxylic acid (6b) 
Dark red solid. Yield: 7.883 g (86%); mp.: 114-117 °C; []D
25: −23.9° (CHCl3 c = 0.071 g/100 mL); IR 
(cm
−1
): ~3600-2800, 1735, 1690, 1640, 1570, 1458, 1443, 1369, 1254, 1106, 1005, 823, 742. 
1
H NMR (DMSO-
d6): 10.89 (s, 1H, NH); 8.43 (s, 1H, CH=N); 7.56 (d, J=7.3 Hz, 1H, H4); 7.32 (d, J=7.3 Hz, 1H, H7); 7.06 (t, 
J=7.3 Hz, 1H, H6); 6.99 (t, J=7.3 Hz, 1H, H5); 7.15 (d, J=1.8 Hz, 1H, H2); 5.07 (br s, 1H, H5’); 4.83 (br s, 1H, 
H3’); 4.70 (t, J=2.0 Hz, 1H, H4’); 4.49 (dd, J=8.9 and 4.6 Hz, H, N-CH); 4.13 (s, 5H, 5-C5H5); 3.72 (s, 3H, 
CO2CH3), 3.38 (dd, J=14.5 and 4.6 Hz, 1H, C-CHAHB, partly overlapped by the HDO signal of the solvent); 3.19 
(dd, J=14.5 and 8.9 Hz, 1H, C-CHAHB) due to exchange processes the signal of CO2H proton could not be 
detected in the spectrum; 
13
C NMR (DMSO-d6): 171.4 (CO2H); 171.0 (CO2CH3); 167.5 (CH=N); 136.6 (C7a); 
127.3 (C3a); 124.5 (C2); 121.5 (C6); 119.1 (C5);118.7 (C4), 112.1 (C7); 109.5 (C3); 76.5 (C5’); 75.5 (C3’); 73.5 
(C4’); 73.2 (C1’); 71.9 (5-C5H5); 70.2 (C2’); 70.7 (N-CH); 53.2 (CO2CH3); 28.6 (C-CH2); Anal. Calcd. for 
C24H22FeN2O4 (458.30): C, 62.90; H, 4.84; N, 6.11. Found: C: 63.04; H: 4.77; N, 6.20%. 
 
4.3. Pictet-Spengler cyclizations of imine 2a by Methods C-G: synthesis of 1-ferrocenyl-2,3,4,9-tetrahydro-1H-
pyrido[3,4-b]indole (3a) 
 Imine 2a (3.563 g, 10 mmol) was added to the corresponding acidic mixture ((Method C: 70% 
HClO4/EtOH (1 mL/15 mL); Method D: 70% HClO4/AcOH (1 mL/15 mL); Method E: TFA/AcOH (1 mL/15 
mL); Method F: H3BO3/AcOH (0.350 g/15 mL); Method G: AcOH (15 mL)) The resulted solution was stirred 
and heated at reflux (for 24 h by Methods C and G and for 4h by Methods D-F) under argon and evaporated to 
dryness. The residue was triturated with water and the pH of the resulted suspension was adjusted to 8-9 by 
addition of solid Na2CO3 in small portions. The solid precipitate was collected by filtration, washed with cold 
EtOH and dried to obtain 3a. An analytical sample was recrystallized from EtOH. Yield: 1.283 g (36% by 
Method C); 0.891 g (25% by Method D); 1.603 g (45% by Method E); 1.960 g (55% by Method F); 2.850 g 
(80% by Method G); mp.: 98-100 °C; Rf: 0.30; IR (cm
−1
): 3423, 3232, 1642, 1620, 1584, 1455, 1415, 1294, 




1103, 999, 820, 743. 
1
H NMR (DMSO-d6): 10.17 (s, 1H, NH); 7.34 (dd, J=7.4 and 1.8 Hz, 1H, H5); 7.28 (br d, 
J=7.4 Hz, 1H, H8); 6.98 (td, J=7.4 and 1.8 Hz, 1H, H7); 6.92 (td, J=7.4 and 1.8 Hz, 1H, H6); 4.84 (s, 1H, H1); 
4.48, 4.31, 4.17, 4.09 (4xbr s, 4x1H, H2’-5’); 4.19 (s, 5H, 5-C5H5); 3.30 (dt, J=12.1 and 3.1 Hz, 1H, H3A, partly 
overlapped by the HDO signal of the solvent); 2.99 (ddd, J=12.1, 7.6 and 4.8 Hz, 1H, H3B); 2.69-2.57 
(overlapping m’s, 2H, H4A and H4B); 
13
C NMR (DMSO-d6): 137.4 (C9a); 136.6 (C8a); 127.6 (C4b); 121.2 (C7); 
119.1 (C6); 118.5 (C5); 112.2 (C8); 107.4 (C4a); 92.2 (C1’); 68.6, 67.9, 67.8, 66.7 (C2’-5’); 69.3 (5-C5H5); 
52.6 (C1); 43.5 (C3); 23.3 (C4); Anal. Calcd. for C21H20FeN2 (356.25): C, 70.80; H, 5.66; N, 7.86. Found: C: 
70.68; H: 5.60; N, 7.77%.  
4.4. Pictet-Spengler cyclizations of imines 2b and 6a,b by Method G: 
The conversion of the appropriate imine (10 mmol) was performed in AcOH (15 mL). The workup 
procedure described in the previous section led to the isolation of diastereomeric mixtures of the appropriate -
carboline products (3b/4b, 7a/8a and 7b/8b). (After the reactions of 6a and 6b the pH of the suspensions 
obtained by trituration of the evaporated reaction mixture with water was adjusted to 7-8 by addition of solid 
Na2CO3 in small portions.) The diastereomeric pairs were subjected to flash column chromatography on silica 
using DCM-MeOH (20:1 for 3b/4b, 10:1 for 7a/8a, and 15:1 for 7b/8b) as eluents. The solid residues obtained 
by evaporation of separated bands were triturated by cold MeOH, filtered off and dried to give -carbolines as 
single diastereomers. Analytical samples were recrystallized from MeOH.  
4.4.1. Methyl (1S,3S)-1-ferrocenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (3b) 
 Dark yellow solid. Yield: 2.569 g (62%); mp.: 97-100 °C; Rf: 0.41; []D
25: −62.0° (CHCl3 c = 0.064 
g/100 mL); IR (cm
−1
): 3354, 3204, 1622, 1573, 1423, 1380, 1287, 1085, 975, 810, 748. 
1
H NMR (DMSO-d6): 
10.24 (s, 1H, NH); 7.46 (br d, J=7.6 Hz, 1H, H5); 7.19 (br d, J=7.6 Hz, 1H, H8); 7.02 (td, J=7.6 and 1.8 Hz, 1H, 
H7); 6.95 (td, J=7.6 and 1.8 Hz, 1H, H6); 4.84 (s, 1H, H1); 4.68, 4.31, 4.17, 4.10 (4xbr s, 4x1H, H2’-5’); 4.32 (s, 
5H, 5-C5H5); 4.07 (dd, , J=11.9 and 4.4 Hz, 1H, H3); 3.90 (s, 3H, OCH3); 3.05 (dd, J=14.5 and 4.8 Hz, 1H, 
H4B); 2.83 (dd, J=14.5 and 11.9 Hz, 1H, H4A); 
13
C NMR (DMSO-d6): 138.3 (C8a); 135.8 (C9a); 127.0 (C4b); 
122.0 (C7); 120.3 (C6); 118.6 (C5); 112.9 (C8); 106.5 (C4a); 91.8 (C1’); 72.0 (5-C5H5); 69.3, 68.4, 68.1, 66.9 
(C2’-5’); 50.0 (C1); 54.7 (C3); 25.2 (C4); Anal. Calcd. for C23H22FeN2O2 (414.29): C, 66.68; H, 5.35; N, 6.76;. 
Found: C: 66.80; H: 5.31; N, 6.70%.  
4.4.2. Methyl (1R,3S)-1-ferrocenyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate (4b) 
 Dark yellow solid. Yield: 0.497 g (12%); mp.: 113-115 °C; Rf: 0.53; []D
25: −71.7° (EtOH c = 0.062 
g/100 mL); IR (cm
−1
): 3408, 3222, 1615, 1573, 1445, 1364, 1186, 1103, 988, 814, 740. 
1
H NMR (DMSO-d6): 
10.52 (s, 1H, NH); 7.42 (br d, J=7.6 Hz, 1H, H5); 7.36 (br d, J=7.6 Hz, 1H, H8); 7.00 (br t, J=7.6 Hz, 1H, H7); 
6.85 (br t, J=7.6 Hz, 1H, H6); 5.24 (s, 1H, H1); 4.53, 4.29, 4.22, 4.07 (4xbr s, 4x1H, H2’-5’); 4.13 (dd, , J=5.4 
and 4.2 Hz, 1H, H3); 3.96 (s, 5H, 5-C5H5); 3.73 (s, 3H, OCH3); 3.19 (dd, J=15.6 and 4.2 Hz, 1H, H4B); 2.83 
(dd, J=15.6 and 5.4 Hz, 1H, H4A); 
13
C NMR (DMSO-d6): 136.1 (C8a); 132.3 (C9a); 127.4 (C4b); 122.4 (C7); 
120.2 (C6); 119.4 (C5); 111.6 (C8); 106.2 (C4a); 90.3 (C1’); 70.7 (5-C5H5); 68.1, 67.5, 67.0, 66.5 (C2’-5’); 
50.0 (C1); 51.2 (C3); 24.0 (C4); Anal. Calcd. for C23H22FeN2O2 (414.29): C, 66.68; H, 5.35; N, 6.76;. Found: C: 
66.77; H: 5.44; N, 6.82%.  
4.4.3. (Sp)-((S)-5-(2,3,4,9-Tetrahydro-1H-pyrido[3,4-b]indol-1-yl))ferrocene-1-carboxylic acid (7a) 
 Orange solid. Yield: 1.241 g (31%); mp.: 193-195 °C; Rf: 0.36; []D
25
: +20.9° (CHCl3 c = 0.033 g/100 
mL); IR (cm
−1
): ~3600-2700, 1612, 1563, 1440, 1365, 1265, 1106, 1005, 815, 735. 
1
H NMR (DMSO-d6): 10.20 
(s, 1H, NH); 7.45 (br d, J=7.5 Hz, 1H, H5); 7.35 (br d, J=7.5 Hz, 1H, H8); 7.09 (td, J=7.5 and 1.8 Hz, 1H, H7); 
7.04 (td, J=7.5 and 1.8 Hz, 1H, H6); 5.88 (s, 1H, H1); 4.80 (br s, 1H, H3’); 4.57 (br s, 1H, H4’); 4.51 (br s, 1H, 
H5’); 4.37 (s, 5H, 5-C5H5); 3.51 (ddd, , J=12.6, 6.9 and 5.0 Hz, 1H, H3A); 3.35 (ddd, J=12.6, 6.2 and 4.5 Hz, 
1H, H3B); 3.01-2.79 (overlapping m’s, 2H, H4A and H4B); 
13
C NMR (DMSO-d6): 171.0 (CO2); 137.8 (C8a); 
133.3 (C9a); 127.5 (C4b); 122.2 (C7); 119.7 (C6); 119.2 (C5); 112.9 (C8); 104.7 (C4a); 90.8 (C1’); 73.8 (C5’); 
71.5 (C2’); 71.0 (5-C5H5); 70.6 (C4’); 70.2 (C3’); 53.1 (C1); 43.5 (C3); 20.2 (C4); Anal. Calcd. for 
C22H20FeN2O2 (400.26): C, 66.02; H, 5.04; N, 7.00; Found: C: 65.97; H: 5.13; N, 6.94%.  
4.4.4. 2-(Sp)-((1S,3S)-3-(Methoxycarbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)ferrocene-1- 
carboxylic acid (7b) 
Red solid. Yield: 1.512 g (33%); mp.: 181-184 °C; Rf: 0.55; []D
25: −27.5° (CHCl3 c = 0.060 g/100 
mL); IR (cm
−1
): ~3500-2900, 1746, 1603, 1540, 1438, 1364, 1267, 1219, 1106, 1002, 915,819, 737. 
1
H NMR 
(DMSO-d6): 10.32 (s, 1H, NH, indole); 7.44 (br d, J=7.7 Hz, 1H, H5); 7.25 (br d, J=7.7 Hz, 1H, H8); 7.03 (br t, 




J=7.7 Hz, 1H, H7); 6.97 (td, J=7.7 and 1.7 Hz, 1H, H6); 5.17 (s, 1H, H1); 4.78 (br s, 1H, H5’); 4.72 (br s, 1H, 
H3’); 4.61 (t, J=2.1 Hz, 1H, H4’); 4.46 (s, 5H, 5-C5H5); 4.10 (dd, J=11.7 and 4.3 Hz, 1H, H3); 3.87 (s, 3H, 
CO2CH3); 3.18 (dd, , J=14.9 and 4.3 Hz, 1H, H4A); 2.88 (ddd, , J=14.9, 11.7 and 1.9 Hz, 1H, H4B); 
13
C NMR 
(DMSO-d6):172.4 (CO2CH3); 171.2 (CO2

); 137.0 (C8a); 133.1 (C9a); 126.5 (C4b); 121.7 (C7); 119.4 (C6); 
118.5 (C5); 111.9 (C8); 105.5 (C4a); 89.2 (C1’); 74.5 (C5’); 73.5 (C4’); 72.3 (C3’); 70.9 (C2’); 70.6 (5-C5H5); 
55.9 (C3); 52.8 (CO2CH3); 51.4 (C1); 24.3 (C4); Anal. Calcd. for C24H22FeN2O4 (458.30): C, 62.90; H, 4.84; N, 
6.11; Found: C: 62.84; H: 4.95; N, 6.14%. 
4.4.5. (Sp)-((R)-5-(2,3,4,9-Tetrahydro-1H-pyrido[3,4-b]indol-1-yl))ferrocene-1-carboxylic acid (8a) 
Orange solid. Yield: 0.112 g (14%); mp.: 162-164 °C; Rf: 0.49; []D
25: −20.1° (CHCl3 c = 0.028 g/100 mL); IR 
(cm
−1
): ~3650-2750, 1621, 1560, 1451, 1357, 1270, 1103, 995, 808, 740; 
1
H NMR (DMSO-d6): 10.68 (s, 1H, 
NH, indole); 7.46 (br d, J=7.5 Hz, 1H, H5); 7.25 (br d, J=7.5 Hz, 1H, H8); 7.05 (td, J=7.5 and 1.8 Hz, 1H, H7); 
7.01 (td, J=7.5 and 1.8 Hz, 1H, H6); 5.45 (s, 1H, H1); 4.85 (br s, 1H, H3’); 4.61 (br s, 1H, H5’); 4.48 (br s, 1H, 
H4’); 4.02 (s, 5H, 5-C5H5); 3.73 (ddd, , J=12.5, 6.2 and 4.0 Hz, 1H, H3A); 3.23 (ddd, J=12.5, 5.2 and 4.1 Hz, 
1H, H3B); 2.94-2.74 (overlapping m’s, 2H, H4A and H4B); 
13
C NMR (DMSO-d6): 170.8 (CO2); 137.0 (C8a); 
132.9 (C9a); 127.1 (C4b); 121.7 (C7); 120.0 (C6); 118.6 (C5); 112.5 (C8); 106.9 (C4a); 89.1 (C1’); 74.6 (C5’); 
72.0 (C2’); 70.8 (5-C5H5); 70.6 (C4’); 70.0 (C3’); 52.2 (C1); 41.3 (C3); 20.6 (C4); 
4.4.6. 2-(Sp)-((1R,3S)-3-(Methoxycarbonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)ferrocene-1-
carboxylic acid (8b) 
 Red solid. Yield: 1.283 g (28%); mp.: 174-178 °C; Rf: 0.48; []D
25: −63.4° (CHCl3 c = 0.040 g/100 
mL); IR (cm
−1
):~ 3450-2900, 1742, 1607, 1553, 1441, 1362, 1259, 1224, 1102, 998, 905,822, 741. 
1
H NMR 
(DMSO-d6): 10.34 (s, 1H, NH, indole); 7.44 (br d, J=7.7 Hz, 1H, H5); 7.30 (br d, J=7.7 Hz, 1H, H8); 7.06 (br t, 
J=7.7 Hz, 1H, H7); 6.98 (td, J=7.7 and 1.7 Hz, 1H, H6); 5.56 (s, 1H, H1); 4.74 (br s, 1H, H3’); 4.57 (br s, 1H, 
H5’); 4.55 (br s, 1H, H4’); 4.27 (dd, J=5.7 and 4.2 Hz, 1H, H3A); 3.85 (s, 5H, 
5
-C5H5); 3.68 (s, 3H, CO2CH3); 
3.15-3.11 (overlapping m’s, 2H, H4A and H4B); 
13
C NMR (DMSO-d6):173.4 (CO2CH3); 170.3 (CO2); 137.3 
(C8a); 133.4 (C9a); 127.0 (C4b); 122.2 (C7); 119.7 (C6); 118.9 (C5); 112.4 (C8); 105.2 (C4a); 89.7 (C1’); 74.4 
(C5’); 71.2 (5-C5H5); 70.9 (C2’); 70.5 (C4’); 70.2 (C3’); 53.1 (C3); 52.3 (CO2CH3); 49.7 (C1); 23.6 (C4); Anal. 
Calcd. for C24H22FeN2O4 (458.30): C, 62.90; H, 4.84; N, 6.11; Found: C: 62.98; H: 4.90; N, 6.05%. 
4.5. Cyclization of 7a with cyanuricfluoride: synthesis of (12bS,Sp,P)-4-Oxo-6,7,12,12b-tetrahydro-4H-
ferroceno[1,2]indolizino[8,7-b]indole-5-one (9a) by Method H 
-Carboline 7a (4.003 g, 10 mmol) was dissolved in dry DCM (50 mL). To this solution pyridine (1.650 
mL) and cyanuricfluoride (3.605 mL) were added at 0 °C. After a few minutes the cooling bath was removed and 
the mixture was stirred at rt for 90 minutes under Ar. After addition of crushed ice the resulted suspension was 
filtered, the organic phase was separated, washed with cold water (3x50 mL), dried over Na2SO4, filtered and 
evaporated. The crude lactame was purified by flash column chromatography on silica using DCM-MeOH (30:1) 
as eluent. The orange band was collected, evaporated and triturated with cold EtOH to obtain 9a in pure form as 
red needles. Yield: 1.477 g (45%); mp.: 103-105 °C; Rf: 0.74; []D
25
: +55.4° (CHCl3 c = 0.048 g/100 mL); IR 
(cm
−1
): 3222, 1621, 1521, 1447, 1368, 1303, 1247, 1158, 1106, 1003, ,829, 742. 
1
H NMR (CDCl3): 9.11 (s, 1H, 
NH); 7.59 (br d, J=7.6 Hz, 1H, H8); 7.48 (br d, J=7.6 Hz, 1H, H11); 7.27 (td, J=7.6 and 1.9 Hz, 1H, H10); 7.18 
(td, J=7.6 and 1.9 Hz, 1H, H9); 6.95 (s, 1H, H12b); 5.18 (br dd, J=13.1 and 5.2 Hz, 1H, H6B); 4.96 (br s, 1H, 
H1); 4.59 (t, J=2.0 Hz, 1H, H2); 4.55 (br s, 1H, H3); 4.06 (s, 5H, 5-C5H5); 3.79 (ddd, J=13.1, 11.6 and 5.2 Hz, 
1H, H6A); 3.13-3.12 (overlapping m’s, 2H, H7A and H7B); 
13
C NMR (CDCl3):168.3 (C4); 135.7 (C11a); 133.1 
(C12a); 125.8 (C7b); 123.2 (C10); 120.2 (C9); 119.1 (C8); 111.4 (C11); 107.9 (C7a); 92.3 (C12c); 74.2 (C3); 
72.5 (C1); 71.6 (C2); 71.5 (5-C5H5); 60.0 (C3a); 50.0 (C12b); 41.3 (C6); 21.3 (C7); Anal. Calcd. for 
C22H18FeN2O (382.24): C, 69.13; H, 4.75; N, 7.33; Found: C: 69.23; H: 4.80; N, 7.24%. 
4.6. Cyclization of 6a,b, 7a,b and 8a,b with carbonyldiimidazole by Method I 
The mixture of 5 mmol of the corresponding imine (6a,b) or -carboline (7a,b and 8a,b), 
carbonyldiimidazole (CDI, 0.474 g, 6 mmol) and NEt3.HCl (0.069 g, 1 mmol) disslolved in dry DMF (10 mL) 
was stirred under an Ar atmosphere at 50 
o
C for 30 min. The reaction mixture was poured on ice-water and the 
resulted precipitate was filtered off, washed with water, dried and subjected to flash column chromatography on 
silica using DCM-MeOH (30:1) as eluent. Lactames 9a,b, 9b/inv 12a,b, 14b and cyclopenta[7,8]azonino[5,4-
b]indole 13b obtained by the evaporation of the separated bands were crystallized by cold MeOH. The analytical 
and spectral data of lactame 9a (1.147 g, 60% from 7a and 0.456 g, 24% from 6a) were practically identical to 
those measured for the sample prepared by Method H. 




4.6.1. (12bR,Sp,M)-4-Oxo-6,7,12,12b-tetrahydro-4H-ferroceno[1,2]indolizino[8,7-b]indole-5-one (12a) 
Red solid. Yield: 2.219 g (58% by from 6a); 1.682 g (44% by from 8a); mp.: 126-128 °C; Rf: 0.82; 
[]D
25
: +56.3° (CHCl3 c = 0.024 g/100 mL);; IR (cm
−1
):~ 3400-2950, 1685, 1611, 1559, 1451, 1375, 1270, 1233, 
1106, 901,830, 749. 
1
H NMR (CDCl3): 9.24 (s, 1H, NH); 7.54 (br d, J=7.8 Hz, 1H, H8); 7.36 (br d, J=7.8 Hz, 
1H, H11); 7.21 (br t, J=7.8, 1H, H10); 7.14 (td, J=7.6 and 1.9 Hz, 1H, H9); 6.33 (s, 1H, H12b); 4.98 (ddd, 
J=14.6, 5.4 and 2.0 Hz, 1H, H6A); 4.78 (br s, 1H, H1); 4.52 (t, J=2.2 Hz, 1H, H2); 4.41 (br s, 1H, H3); 3.68 (s, 
5H, 5-C5H5); 3.54 (ddd, J=14.6, 11.2 and 5.4 Hz, 1H, H6B); 3.25-3.18 (overlapping m’s, 2H, H7A and H7B); 
13
C 
NMR (CDCl3):167.1 (C4); 131.6 (C11a); 129.8 (C12a); 124.6 (C7b); 123.0 (C10); 121.0 (C9); 119.4 (C8); 112.1 
(C11); 106.7 (C7a); 90.9 (C12c); 74.0 (C3); 71.1 (C1); 70.6 (C2); 70.2 (5-C5H5); 63.1 (C3a); 48.2 (C12b); 41.0 
(C6); 21.6 (C7); Anal. Calcd. for C22H18FeN2O (382.24): C, 69.13; H, 4.75; N, 7.33; Found: C: 69.01; H: 4.82; 
N, 7.19%.  
4.6.2. Methyl (6S,12bS,Sp,P)-4-oxo-6,7,12,12b-tetrahydro-4H-ferroceno[1,2]indolizino[8,7-b]indole-6-
carboxylate (9b) 
Red solid. Yield: 0.220 g (5% from 6b); 1.631 g (37% from 7b); mp.: 101-104 °C; Rf: 0.57; []D
25
: 
−32.9° (CHCl3 c = 0.039 g/100 mL); IR (cm
−1
):~ 3400-2850, 1740, 1628, 1543, 1451, 1369, 1262, 1230, 1105, 
992, 900,811, 751. 
1
H NMR (CDCl3): 8.81 (s, 1H, NH); 7.58 (dd, J=7.6 and 1.8 Hz, 1H, H8); 7.47 (br d, J=7.6 
Hz, 1H, H11); 7.06 (td, J=7.6 and 1.8 Hz, 1H, H10); 6.98 (td, J=7.6 and 1.9 Hz, 1H, H9); 5.89 (s, 1H, H12b); 
4.91 (br s, 1H, H1); 4.55 (br s, 1H, H3); 4.27 (s, 5H, 5-C5H5); 4.22 (t, J=2.0 Hz, 1H, H2); 4.18 (dd, J=11.8 and 
4.3 Hz, 1H, H6A); 3.97 (s, 3H, CO2CH3); 3.29 (dd, J=15.9 and 11.8 Hz, 1H, H7B); 3.09 (dd, J=15.9 and 4.3 Hz, 
1H, H7A); 
13
C NMR (CDCl3):173.2 (C4); 170.2 (CO2CH3); 136.3 (C11a); 130.7 (C12a); 126.4 (C7b); 122.4 
(C10); 119.9 (C9); 118.6 (C8); 111.4 (C11); 105.7 (C7a); 94.0 (C12c); 75.5 (C3a); 72.6 (C2); 70.2 (C3); 68.1 
(C1); 71.0 (5-C5H5); 55.6 (C6); 52.5 (CO2CH3); 51.1 (C12b); 23.4 (C7); Anal. Calcd. for C24H20FeN2O3 




Red solid. Yield: 0.661 g (15% from 6b); mp.: 92-95 °C; Rf: 0.65; []D
25: −27.6° (CHCl3 c = 0.041 
g/100 mL); IR (cm
−1
):~ 3450-2850, 1742, 1634, 1543, 1472, 1381, 1242, 1222, 1121, 1008, 919, 835, 772. 
1
H 
NMR (CDCl3): 8.29 (s, 1H, NH); 7.50 (br d, J=7.7 Hz, 1H, H8); 7.35 (br d, J=7.7 Hz, 1H, H11); 7.19 (td, J=7.7 
and 1.8 Hz, 1H, H10); 7.13 (td, J=7.7 and 1.8 Hz, 1H, H9); 6.30 (s, 1H, H12b); 5.64 (d, J=7.1 Hz, 1H, H6A); 
4.94 (br s, 1H, H1); 4.70 (br s, 1H, H3); 4.31 (s, 5H, 5-C5H5); 4.29 (t, J=2.0 Hz, 1H, H2); 3.78 (s, 3H, 
CO2CH3); 3.41 (d, J=15.9 Hz, 1H, H7B); 3.22 (dd, J=15.9 and 7.1 Hz, 1H, H7A); 
13
C NMR (CDCl3):172.3 (C4); 
172.0 (CO2CH3); 136.1 (C11a); 130.7 (C12a); 126.6 (C7b); 122.6 (C10); 120.1 (C9); 118.7 (C8); 111.1 (C11); 
106.7 (C7a); 95.1 (C12c); 76.5 (C3a); 72.6 (C2); 71.0 (5-C5H5); 64.0 (C1); 62.4 (C3); 53.5 (C12b); 52.6 
(CO2CH3); 50.1 (C6); 24.1 (C7); Anal. Calcd. for C24H20FeN2O3 (440.28): C, 65.47; H, 4.58; N, 6.36; Found: C: 




Red solid. Yield: 1.167 g (53% from 6b); 0.572 g (26% from 8b); mp.: 116-118 °C; Rf: 0.68; []D
25
: 
+75.0° (CHCl3 c = 0.046 g/100 mL); IR (cm
−1
):~ 3500-2850, 1748, 1630, 1549, 1442, 1370, 1284, 1220, 1113, 
1002, 905, 820, 764; 
1
H NMR (CDCl3): 9.17 (s, 1H, NH); 7.59 (br d, J=7.8 Hz, 1H, H8); 7.47 (br d, J=7.8 Hz, 
1H, H11); 7.06 (br t, J=7.8 Hz, 1H, H10); 6.98 (br t, J=7.8 Hz, 1H, H9); 5.82 (s, 1H, H12b); 5.66 (d, J=7.5 Hz, 
1H, H6A); 4.73 (br s, 1H, H1); 4.71 (br s, 1H, H3); 4.33 (t, J=2.2 Hz, 1H, H2); 3.70 (s, 5H, 
5
-C5H5); 3.67 (s, 
3H, CO2CH3); 3.56 (d, J=15.9 Hz, 1H, H7B); 3.24 (dd, J=15.9 and 7.5 Hz, 1H, H7A); 
13
C NMR (CDCl3): 171.6 
(CO2CH3); 171.3 (C4); 136.1 (C11a); 132.4 (C12a); 126.56 (C7b); 122.4 (C10); 119.9 (C9); 118.6 (C8); 111.3 
(C11); 105.4 (C7a); 94.8 (C12c); 78.3 (C3a); 72.4 (C2); 69.8 (5-C5H5); 62.9 (C1); 61.8 (C3); 52.4 (CO2CH3); 
51.9 (C12b); 50.2 (C6); 24.3 (C7); Anal. Calcd. for C24H20FeN2O3 (440.28): C, 65.47; H, 4.58; N, 6.36; Found: 
C: 65.62; H: 4.51; N, 6.45%. 
 
4.6.5. Methyl (6S,Z)-4-oxo-5,6,7,12-tetrahydro-4H-cyclopenta[7,8]azonino[5,4-b]indole-6-carboxylate (13b) 
Light yellow powder. Yield: 0.096 g (6% from 6b); 0.144 g (9% from 7b); 0.352 g (22% by Method L 
from 9b); 0,256 g (16% by Method L from 9b/inv); mp.: 198-201 °C; Rf: 0.24; []D
25
: +18.2° (CHCl3 c = 0.026 
g/100 mL); IR (cm
−1
):~ 3300-2700, 1746, 1638, 1536, 1486, 1353, 1275, 1251, 1113, 1094, 958; 
1
H NMR 
(CDCl3): 9.25 (s, 1H, índole NH); 7.42 (br d, J=7.7 Hz, 1H, H8); 7.37 (br d, J=7.7 Hz, 1H, H11); 7.06 (td, J=7.7 




and 1.9 Hz, 1H, H10); 7.00 (td, J=7.7 and 1.9 Hz, 1H, H9); 6.70 (br s, 1H, H13); 6.76 (br d, J=4.6 Hz, 1H, H3); 
6.70 (br d, J=8.8 Hz, 1H, H2); 6.64 (br d, J=8.8 Hz, 1H, H1); 6.56 (d, J=7.4 Hz, 1H, lactame NH); 5.09 (ddd, 
J=7.4, 5.5 and 2.5 Hz, 1H, H6); 3.68 (s, 3H, , CO2CH3); 3.45 (dd, J=14.7 and 5.5 Hz, 1H, H7B); 3.39 (dd, J=14.7 
and 2.5 Hz, 1H, H7A); 
13
C NMR (CDCl3): 173.0 (CO2CH3); 166.7 ((C4); 135.8 (C13a); 132.3 (C11a); 130.4 
(C12a); 127.6 (C7b); 123.5 (C13); 122.6 (C10); 122.1 (C1); 120.2 and 120.1 (C2 and C3); 119.4 (C9); 118.8 
(C8); 114.5 (C3a); 111.8 (C11); 110.1 (C7a); 54.3 (CO2CH3); 52.7 (C6); 28.0 (C7); 
Anal. Calcd. for C19H16N2O3 (320.35): C, 71.24; H, 5.03; N, 8.74; Found: C: 71.39; H: 4.97; 8.68%. 
 
4.6.6. Methyl 7-oxo-7H-ferroceno[c]indolo[3,2,1-ij][1,5]naphthyridine-2-carboxylate (14b) 
Deep red solid. Yield: 0.480 g (22% from 7b); 0.654 g (30% from 8b); mp.: 202-203 °C; Rf: 0.82; 
[]D
25
: +32.0° (CHCl3 c = 0.051 g/100 mL); IR (cm
−1
): 2894, 1722, 1673, 1571, 1440, 1412, 1375, 1297, 1250, 
1197,1180, 1012, 806, 791; 
1
H NMR (CDCl3): 8.90 (s, 1H, H1); 8.62 (br d, J=7.9 Hz, 1H, H9); 8.51 (br d, J=7.9 
Hz, 1H, H12); 7.79 (td, J=7.9 and 1.8 Hz, 1H, H10); 7.59 (td, J=7.9 and 1.8 Hz, 1H, H11); 5.64 (dd, J=2.5 and 
1.6 Hz, 1H, H4); 5.44 (dd, J=2.5 and 1.6 Hz, 1H, H6); 5.02 (t, J=2.5 Hz, 1H, H5); 4.12 (s, 5H, 5-C5H5); 4.00 (s, 
3H, OCH3); 
13
C NMR (CDCl3): 167.2 (C7); 166.0 (CO2CH3); 146.4 (C2); 142.7 (C3a); 139.0 (C8a); 133.5 
(C12c); 131.1 (C10); 125.4 (C11); 125.0 (C12a); 124.0 (C12b); 123.9 (C12); 116.6 (C9); 116.5 (C1); 81.6 
(C3b); 74.7 (C5); 73.6 (C6a); 71.7 (5-C5H5); 70.0 (C6); 67.8 (C4); 53.0 (CO2CH3); Anal. Calcd. for 
C24H16FeN2O3 (436.25): C, 66.08; H, 3.70; N, 6.42; Found: C: 65.97; H: 3.62; N, 6.48%.  
 
4.7. Acylation of tryptamine with (Sp)-2-formylferrocenecarbonylfluoride (10): synthesis of (Sp)-N-(2-(1H-indol-
3-yl)ethyl)-2-formylferrocene-1-carboxamide (11) by Method J 
The mixture of tryptamine (1.601 g, 10 mmol), 10 (2.601 g, 10 mmol) and dry THF (40 mL) was stirred 
under argon at 25 
o
C for 24 h then evaporated to dryness. The residue was triturated with 20 mL of EtOH-H2O 
(1:3), filtered off and dried to give amide 11 as a dark orange solid. Yield: 2.842 g (71%); mp.: 204-207 °C; 
[]D
25
: +34.2° (EtOH c = 0.037 g/100 mL); IR (cm−1):~ 3400-2700, 1695, 1641, 1453, 1337, 1249, 1226, 1125, 
1104, 1020, 883, 827, 738; 
1
H NMR (DMSO-d6): 10.83 (br s, 1H, H1); 10.42 (s, 1H, CHO); 8.54 (t, J=5.6 Hz, 
1H, CONH); 7.62 (br d, J=7.8 Hz, 1H, H4); 7.35 (br d, J=7.8 Hz, 1H, H7); 7.23 (br d, J=2.0 Hz, 1H, H2); 7.08 
(br t, J=7.8 Hz, 1H, H6); 7.01 (br t, J=7.8 Hz, 1H, H5); 5.27 (dd, J=2.6 and 1.5 Hz, 1H, H5’); 4.95 (dd, J=2.6 
and 1.5 Hz, 1H, H3’); 4.83 (t, J=2.6 Hz, 1H, H4’); 4.23 (s, 5H, 5-C5H5); 3.59 and 3.53 (2xm, 2x1H, NCHAHB 
and NCHAHB); 2.99 (t, J=7.3 Hz, 2H, CCH2); 
13
C NMR (DMSO-d6): 196.2 (CHO); 168.9 (CONH); 137.2 (C7a); 
128.2 (C4a); 123.6 (C2); 121.8 (C6); 119.2 and 119.1 (C4 and C5); 112.7 (C3); 112.3 (C7); 80.1 (C1’); 79.2 
(C2’); 75.5 (C5’); 74.1 (C4’); 72.8 (C3’); 72.0 (5-C5H5); 40.6 (NCHAHB); 26.1 (CCH2); Anal. Calcd. for 
C22H20FeN2O2 (400.26): C, 66.02; H, 5.04; N, 7.00; Found: C: 66.20; H: 5.12; N, 6.94%.  
 
4.8. Ring inversion 9b/inv→9b monitored by 1H-NMR spectroscopy 
Lactame 9b/inv (0.044g, 0.1 mmol) was dissolved in DMSO-d6 (1 mL) and the resulted solution was 
subjected to 
1
H-NMR studies. First the 
1
H-NMR spectrum was registered at 300 K, then solution was incubated 
at 363 K for ca. 30 min then cooled down to 300 K, and the 
1
H-NMR spectrum registered showed the presence 
of inverted lactame 9b contaminated with a small amount (ca. 3-5%) of 9b/inv.  
9b/inv: 
1
H NMR (DMSO-d6): 10.75 (br s, 1H, NH, índole), 7.45 (br d, J=7.6 Hz, 1H, H8); 7.29 (br d, 
J=7.6 Hz, 1H, H11); 7.20 (br t, J=7.6 Hz, 1H, H10); 7.13 (td, J=7.7 and 1.8 Hz, 1H, H9); 6.08 (s, 1H, H12b); 
5.55 (d, J=7.3 Hz, 1H, H6A); 5.02 (br s, 1H, H1); 4.65 (br s, 1H, H3); 4.22 (s, 5H, 
5
-C5H5); 4.30 (t, J=2.0 Hz, 
1H, H2); 3.76 (s, 3H, CO2CH3); 3.51 (d, J=15.6 Hz, 1H, H7B); 3.18 (dd, J=15.6 and 7.3 Hz, 1H, H7A); 7.50 (br 
d, J=7.7 Hz, 1H, H8); 7.35 (br d, J=7.7 Hz, 1H, H11); 7.19 (td, J=7.7 and 1.8 Hz, 1H, H10); 7.13 (td, J=7.7 and 
1.8 Hz, 1H, H9); 6.30 (s, 1H, H12b); 5.64 (d, J=7.1 Hz, 1H, H6A); 4.94 (br s, 1H, H1); 4.70 (br s, 1H, H3); 4.31 
(s, 5H, 5-C5H5); 4.29 (t, J=2.0 Hz, 1H, H2); 3.78 (s, 3H, CO2CH3); 3.41 (d, J=15.9 Hz, 1H, H7B); 3.22 (dd, 
J=15.9 and 7.1 Hz, 1H, H7A);  
9b: 
1
H NMR (DMSO-d6): 10.54 (s, 1H, NH, indole); 7.52 (br d, J=7.6 Hz, 1H, H8); 7.40 (br d, J=7.6 
Hz, 1H, H11); 7.06 (br t, J=7.6 Hz, 1H, H10); 6.98 (br t, J=7.6 Hz, 1H, H9); 5.94 (s, 1H, H12b); 4.85 (br s, 1H, 
H1); 4.59 (br s, 1H, H3); 4.28 (s, 5H, 5-C5H5); 4.21 (t, J=2.0 Hz, 1H, H2); 4.26 (dd, J=11.3 and 4.6 Hz, 1H, 
H6A); 4.05 (s, 3H, CO2CH3); 3.31 (dd, J=15.7 and 11.3 Hz, 1H, H7B); 3.11 (dd, J=15.7 and 4.6 Hz, 1H, H7A). 
These signals were practically identical to those discernible in the 
1
H-NMR spectrum of an original sample of 9b 
registered in DMSO-d6 solution in a separate experiment. 




4.9. Imidazole-mediated ring enlargement of lactames 9b and 9b/inv associated with the decomposition of the 
ferrocene residue: synthesis of 13b by Method L. 
The corresponding lactame (0.440 g, 1 mmol) and imidazole (0.082 g, 1.2 mmol) were dissolved in 
DMF (4 mL). The solution was stirred at 110 
o
C for 20 min under argon. The dark reaction mixture was poured 
onto cold water (30 mL) and the resulted suspension was extracted with DCM (3x40 mL). The combined organic 
phase was washed with water (5x50 mL), dried over Na2SO4 and evaporated to dryness. The dark solid residue 
was subjected to flash column chromatography over silica using DCM-MeOH (10:1) as eluent. The evaporation 
of the first orange band recovered 9b as evidenced by 
1
H NMR data practically identical to those presented in 
section 4.5.2. Yield: 0.251 g (57% from 9b) and 0.216 g (49% from 9b/inv). (Under the employed conditions 
ring inversion 9b/inv→9b obviously accompanies the conversion leading to 13b.) Changing eluent to DCM-
MeOH (5:1) allowed the isolation of 13b as light yellow powder. Yield: 0.070 g (22% from 9b) and 0.051 g 
(16% from 9b/inv). The analytical and spectral data were practically identical to those measured for the sample 
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